Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus Target Price from Brokerages

Sana Biotechnology, Inc. (NASDAQ:SANA) has received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $9.50.

Several analysts have recently weighed in on the company. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Weiss Ratings upgraded Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. Wedbush raised their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research note on Tuesday, April 14th. Finally, Rodman & Renshaw began coverage on Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective on the stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its holdings in shares of Sana Biotechnology by 180.8% during the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after purchasing an additional 1,375,029 shares during the period. BIT Capital GmbH acquired a new position in shares of Sana Biotechnology in the 4th quarter valued at about $236,000. ProShare Advisors LLC boosted its holdings in shares of Sana Biotechnology by 31.5% in the 4th quarter. ProShare Advisors LLC now owns 42,126 shares of the company’s stock valued at $171,000 after buying an additional 10,096 shares during the period. Evoke Wealth LLC bought a new stake in shares of Sana Biotechnology during the 4th quarter valued at about $157,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Sana Biotechnology during the 4th quarter valued at about $315,000. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Price Performance

SANA opened at $3.13 on Monday. The firm’s 50 day moving average is $3.27 and its 200-day moving average is $3.53. Sana Biotechnology has a 52-week low of $2.61 and a 52-week high of $6.55. The firm has a market capitalization of $871.05 million, a P/E ratio of -3.37 and a beta of 2.16.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. Equities analysts expect that Sana Biotechnology will post -0.59 earnings per share for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.